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E-mail address: e.naglieri@oncologico.barThe landscape of the treatment of metastatic renal cell carcinoma (RCC) has changed dra-
matically in the last two years. The most promising agents developed and tested were
small molecule tyrosine kinase inhibitors, mammalian target of rapamycin inhibitors
and monoclonal antibodies. Indeed, when compared to IFN-a, first-line therapy with Sun-
itinib, Bevacizumab and Temsirolimus showed an improvement of both progression free
survival (PFS) and survival.
The occurrence and severity of side effects differ between these agents and may define
the choice of the best drug to use in the first line therapy with a model of tailoring therapy.
The adverse events considered to be most important in routine clinical practice are der-
matological toxicities, gastro-intestinal symptoms, stomatitis, hypertension and other car-
diovascular toxicities, haematological toxicity, fatigue and fatigue-causing side effects
including metabolic changes.
We have analyzed and compared the most frequently observed toxicities of these novel
agents in the attempt to obtain an help in the decision making of the best therapy.
Altogether, side effects of targeted agents appear manageable and reversible. Discontin-
uation of treatment due to toxicity is rare. Despite side effects, these novel agents signify
an important step forward.
 2008 Elsevier Ltd. All rights reserved.Renal cell carcinoma (RCC) is a neoplasm highly resistant to
both chemotherapy and radiotherapy.1 Interleukin-2 and
interferon-a have limited efficacy and are associated with
considerable toxic effects.2 In the last 2 years, four targeted
agents were approved for the treatment of advanced renal cell
carcinoma which are changing dramatically the landscape of
the treatment of this pathology. Indeed, when compared to
IFN-a, first-line therapy with sunitinib, bevacizumab and
temsirolimus has shown an improvement of both progres-
sion-free survival (PFS) and survival.
Sunitinib was the first of a new class of drugs to demon-
strate significantly greater efficacy than IFN-a in advanced
RCC. Sunitinib is an orally active inhibitor of tyrosine kinases
(TKI) including vascular endothelial growth factor receptorer Ltd. All rights reserved
i.itand platelet-derived growth factor receptor. These receptor
tyrosine kinases play a role in the pathogenesis of clear-cell
carcinoma and therefore are the optimal targets in the treat-
ment of this neoplasm. In a phase III randomisedmulticentre,
international trial, patients were treated with either 50 mg
once daily in cycles of 4 weeks with 2 weeks of rest or 9
MIU of IFN-a 3 times per week until disease progression or
study withdrawal.3 Primary end-point was PFS and secondary
end-points included objective response rate, overall survival
(OS) and safety. PFS was 11 months for patients treated with
sunitinib and 5 months for those treated with IFN-a
(p < .000001) with a 58% reduction of the risk of progression
or death. The objective response rates were 28% and 5%,
respectively. The most common adverse events are listed in.
Table 2 – Adverse events in patients treated with asso-
ciation between bevacizumab and interferon-alpha
Adverse event All grade (%) Grades 3 and 4 (%)
Diarrhea 20 2
Fatigue 33 12
Nausea 28 0
Stomatitis 30 0
Vomiting 14 0
Hypertension 26 3
Hand–foot syndrome 0 0
rash 0 0
Skin discoloration 0 0
bleeding 33 3
Decline in ejection fraction 1 0
Arterial embolism 1 0
Venous embolism 3 0
Neutropaenia 7 2
Anemia 10 3
Thrombocytopaenia 8 2
Proteinuria 18 0
Hypotiroidism 0 0
Table 1 – Adverse events in patients treated with
sunitinib
Adverse event All grade
(%)
Grade 3
(%)
Grade 4
(%)
Diarrhea 53 5 0
Fatigue 51 7 0
Nausea 44 3 0
Stomatitis 25 1 0
Vomiting 24 4 0
Hypertension 24 8 0
Hand–foot syndrome 20 5 0
Mucosal inflammation 20 2 0
rash 19 1 1
Asthenia 17 4 0
Dry skin 16 1 0
Skin discoloration 16 0 0
Changes in hair colour 14 0 0
Epistaxis 12 1 0
headache 11 1 0
Decline in ejection fraction 10 2 0
Pyrexia 7 1 0
Chills 6 1 0
Leukopaenia 78 5 0
Neutropaenia 72 11 0
Anemia 71 3 1
Thrombocytopaenia 65 8 0
Increased aspartate
aminotransferase
52 2 0
hypotiroidism 71 0 0
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suspending the therapy. A total of 38% of sunitinib group
had a dose interruption because of adverse events, whereas
32% had a dose reduction.
Bevacizumab is an anti-vascular endothelial growth factor
recombinant humanised monoclonal antibody that has
shown efficacy in first-line therapy of metastatic RCC. The
efficacy of bevacizumab in combination with IFN-a as first-
line therapy in metastatic RCC has been compared with that
of IFN-a in two randomised Multicentre phase III trials: the
first was conducted mainly in Europe (AVOREN)4 and the lat-
ter in the United States (US) (CALGB 90206).5 Treatment regi-
mens in the two studies were similar. All patients received
subcutaneous IFN-a 9 MIU three times weekly until disease
progression or unacceptable toxicity (or for a maximum of
52 weeks). Those in the bevacizumab arm of each trial also re-
ceived intravenous bevacizumab 10 mg/kg every 2 weeks until
disease progression or unacceptable toxicity. In AVOREN
study, the median duration of IFN-a in the bevacizumab
arm was 7.8 months (dose intensity 91%). The primary end-
point in both trials was overall survival; secondary end-points
included progression-free survival and objective response
rates. The combination resulted in a median PFS that was sig-
nificantly longer than that seen with IFN-a: 10.2 versus 5.4
months in the AVOREN study and 8.5 versus 5.2 months in
the CALGB 90206 study. Data for overall survival in both stud-
ies have not yet matured.6,7 The addition of bevacizumab to
IFN-a in the AVOREN study was generally well tolerated,
and the adverse events are listed in Table 2. During the course
of AVOREN, the IFN-a dosage was reduced from 9 to 6 or 3 MIU
three times weekly in 41% of the association compared with30% of the IFN arm. Dose reduction seem do not compromise
the efficacy of the combination therapy.
Adverse events occurred in 97% of the combination recip-
ients and 94% of IFN-a recipients in AVOREN. The correspond-
ing incidences of serious adverse events were 29% and 16%.
Bevacizumab-associated toxicities were generally mild in
intensity. The most common grades 3–4 adverse events in
AVOREN study were fatigue and asthenia. Severe adverse
events were reported by 79% of the combination arm in CAL-
GB study compared with 61% when IFN was administered
alone. An approximately 4-fold reduction in incidence of
grades 3–4 adverse events in the 6-week period after dose
reduction compared with the 6-week period before dose
reduction was observed both in bevacizumab plus IFN-a
recipients (8% versus 28%) an placebo plus IFN-a (7% versus
29%) who reduced their IFN dosage during the course of treat-
ment in AVOREN. The discontinuation rate due to adverse
events was 28% in the association arm versus 12% in the
IFN-a arm. For three bevacizumab recipients in AVOREN, the
cause of death was deemed possibly related to the study drug
(two haemorrhage events and one GI perforation).
Therefore, at present we have two regimens available for
the first line of metastatic RCC with either good or intermedi-
ate prognosis. The occurrence and severity of side-effects dif-
fer between these agents and may define the choice of the
best drug to use in the first-line therapy with a model of tai-
loring therapy.
For patients with poor prognosis the best treatment is
temsirolimus. Temsirolimus is an inhibitor of mammalian
target of rapamycin (mTOR) kinase, a component of intracel-
lular signalling pathways involved in the growth and prolifer-
ation of cells8,9 and the response of such cells to hypoxic
stress.10 The inhibition of angiogenesis by temsirolimus is
clinically relevant because unregulated angiogenesis is prom-
inent in RCC. In a phase III randomised trial, temsirolimus
was compared with both IFN- and the association between
the two drugs.11 Temsirolimus was administered intrave-
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icity. Patients who received temsirolimus alone had longer
overall survival (HR for death 0.73; p = 0.008) and PFS
(p = 0.001) than did patients who received IFN alone. Overall
survival in the combination arm did not differed significantly
from that in the interferon group. Median overall survival
times in the IFN group, the temsirolimus group and the com-
bination therapy group were 7.3, 10.9 and 8.4 months, respec-
tively. Adverse events occurred in at least 20% of patients in
any group. Grade 3 or 4 asthenia was reported in 11% of pa-
tients in temsirolimus group and in 28% of those in combina-
tion group. As compared with patients in the IFN group, mild
to moderate rush, peripheral oedema and stomatitis affected
more patients who received temsirolimus either alone or in
combination with IFN.
Another important tyrosine kinase inhibitor is sorafenib.
Sorafenib is an orally active multikinase inhibitor with effects
on tumour cell proliferation and tumour angiogenesis. In a
phase III randomised, double-blind, placebo-controlled trial
(TARGET)12 sorafenib showed an improvement of PFS in pa-
tients with advanced clear-cell RCC in whom previous ther-
apy had failed; median PFS of sorafenib group was 5.5
months compared with 2.8 months of the placebo group.
Diarrhoea, rash, fatigue and hand–foot skin reactions were
the most common adverse events associated with sorafenib.
Adverse events were mainly of grade 1 or 2, and are listed
in Table 3. The proportion of patients who discontinued the
study drug owing to adverse events was similar in the two
groups (10% in the sorafenib group and 8% in the placebo
group) and discontinuation was mostly due to constitutional,
gastro-intestinal or pulmonary-upper respiratory tract symp-
toms. In the sorafenib group doses were reduced in 13 of pa-
tients and were interrupted in 21% of patients (mainly due to
dermatologic and gastro-intestinal events). The median dura-
tion of these interruption was 7 d. Hypertension and cardiac
ischaemia were rare but serious adverse events that were
more common in patients receiving sorafenib than in those
receiving placebo. Cardiac ischaemia or infarction occurredTable 3 – Adverse events in patients treated with
sorafenib (TARGET)
Adverse event All grade (%) Grades 3 and 4 (%)
Diarrhea 43 2
Fatigue 37 5
Nausea 23 1
Stomatitis 21 6
Vomiting 16 1
Hypertension 17 4
Hand–foot syndrome 30 6
rash 40 1
Skin discoloration 0 0
bleeding 15 2
Cardiac ischaemia 3 3
Arterial embolism 0 0
Venous embolism 0 0
Neutropaenia 18 5
Anemia 8 3
Thrombocytopaenia 12 1
Proteinuria 0 0
Hypotiroidism 0 0in 12 patients in the sorafenib group (3%). Of these events,
11 (including 2 deaths) were considered to be serious adverse
events associated with treatment. Bleeding was seen in 15%
of patients. Febrile neutropaenia or grade 4 thrombocytopae-
nia did not occur.
So far we have four new drugs for RCC. Side-effects may be
related to the different targets of the single agents. Indeed
bevacizumab side-effects are related to single target-specific
VEGF. On the contrary, both sunitinib and sorafenib have mul-
ti-targeted-potential for non VEGF related toxicity.
The adverse events considered to be most important in
routine clinical practice are dermatological toxicities, gastro-
intestinal symptoms, stomatitis, hypertension and other car-
diovascular toxicities, haematological toxicity, fatigue and fa-
tigue-causing side-effects including metabolic changes.
The dermatological toxicities affect mainly hands and feet
predominantly on pressure points with dysaesthesia, paraes-
thesia, erithema, callus-like blisters and desquamation.
These aspects are different from the hand–foot syndrome
observed with chemotherapy. For grades 1–2 toxicity it is rec-
ommended to continue at same dose level with supportive
measures. At the first occurrence of grade 3 toxicity, it is nec-
essary to interrupt the treatment until recovery to grades 0–1
resuming the therapy at reduced doses, and subsequently in-
crease to full doses adding supportive measures. At the sec-
ond occurrence of grade 3 toxicity it is mandatory to
interrupt the treatment until recovery, starting and maintain-
ing the reduced doses in the next cycles. Skin toxicities are
never life-threatening and are always reversible, may affect
patient’s daily life and require a close cooperation with
dermatologists.
Diarrhoea is another important event bound to TKIs ther-
apy. Treatment should start at very first signs and patient
should be advised to take loperamide regularly following a
special diet including bananas, rice and potatoes.
The management of cardiovascular side-effects with TKIs
is more complex. It is manageable if the patient’s blood pres-
sure is regularly checked. Treatment interruption or dose
reduction should not be necessary. Blood pressure measure-
ments must be performed daily during the first 3 months of
treatment. The choice of the antihypertensive medication de-
pends on general cardiovascular status of the patient and is
individualised for each patient.
The cardiac side-effects are observed so far predominantly
in patients with TKIs. The relationship to TKIs treatment is
unclear but likely in previously asymptomatic patients. The
possible mechanism is the inhibition of HIF accumulation
by TKI treatment. Side-effects may vary from the reduction
of left ventricular ejection fraction to myocardial infarction.
Before treatment, it is mandatory to evaluate the cardiac
function with both ECG and echocardiography. During treat-
ment an ECG must be repeated monthly and an echocardiog-
raphy every 2–3 months. At the occurrence of cardiac
symptoms it is necessary to interrupt TKI treatment, treat pa-
tients according to the findings and after recovery, resume
treatment based on toxicity grade.
Cancer-related fatigue is a distressing, persistent, subjec-
tive sense of tiredness or exhaustion related to cancer or can-
cer treatment that is not proportional to recent activity and
interferes with usual functioning. Hypotyroidism may be an
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function should be controlled prior to treatment and at
regular intervals. Thyroid replacement therapy should be
started at first increase of TSH.
Haematological toxicities occur mostly at grades 1–2 and
are completely reversible. Intermittent treatment interrup-
tion or dose reduction may be required. Both anaemia and
lymphopaenia do not require dose reduction. Complete blood
counts should be taken before each treatment cycle and on
day 14 of the first 3 months of treatment.
In conclusion, side-effects of targeted agents appear man-
ageable and reversible. Discontinuation of treatment due to
toxicity is rare. Despite side-effects, these novel agents signify
an important step forward.
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